A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

Inclusion Criteria:

- Subject with a diagnosis of definite idiopathic Parkinson's disease (PD) that is
levodopa-responsive according to the United Kingdom Parkinson's Disease Society Brain
Bank Criteria.

- Subject must be taking an optimized and stable regimen of oral medications for PD,
which has remained stable and unchanged for at least 30 days before enrollment in this
study.

- Subject is judged inadequately controlled on current therapy in the opinion of the
Investigator and must experience a minimum of 2.5 hours of "off" time per day prior to
Enrollment.

- Subjects with a MMSE score greater than or equal to 24 and considered by the
Investigator to not have dementia.

Exclusion Criteria:

- Subjects with clinically significant electrocardiogram (ECG) values.

- History of significant skin conditions or disorders that in the Investigator's opinion
would interfere with the infusion of the study drug or could interfere with study
assessments.

- Receipt of an investigational product within at least 6 weeks prior to study drug
administration.

- Subjects with moderate to severe kidney disease.

- Consideration by the investigator for any reason that the subject is an unsuitable
candidate to receive ABBV-951.

- Patient/caregiver that cannot demonstrate proper use of the devices (drug pump and
wearable device) will not be allowed to participate.